Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.


Ocriplasmin is a recombinant protease approved as a nonsurgical treatment for vitreomacular traction (VMT) and small macular holes with vitreomacular adhesion (VMA). Successful ocriplasmin treatment in clinical studies has been defined as nonsurgical resolution of VMA as demonstrated on optical coherence tomography (OCT) by day 28 after intravitreal… (More)
DOI: 10.3928/23258160-20150213-02


  • Presentations referencing similar topics